InsiderTrades

Form 4 for HALO HALOZYME THERAPEUTICS, INC.

Accepted 2024-01-18 00:00:00 ET · period of report 2024-01-16 · accession 0001415889-24-001520 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-01-18 2024-01-16+ HALO LaBarre Michael J. SVP, Chief TECHNICAL Off M - OptEx $12.07 +20.0K 161.9K +14% +$241.4K
DM 2024-01-18 2024-01-16+ HALO LaBarre Michael J. SVP, Chief TECHNICAL Off S - Sale+OE $36.00 -20.0K 151.9K -12% -$720.0K
DM 2024-01-18 2024-01-16+ HALO LaBarre Michael J. SVP, Chief TECHNICAL Off M - OptEx $0.00 -20.0K 34.9K -36% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-01-16 M A 10,000 $12.07 161,911 D — —
2 Common Common Stock 2024-01-17 S D 10,000 $36.00 151,911 D — — (F2) Represents a weighted average sales price per share. These shares were sold at prices ranging from $36.00 to $36.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3 Common Common Stock 2024-01-16 S D 10,000 $36.00 151,911 D — —
4 Common Common Stock 2024-01-17 M A 10,000 $12.07 161,911 D — —
5 Derivative Option to Purchase Common Stock 2024-01-17 M D 10,000 $0.00 24,885 D $12.07 · — to 2027-02-22 10,000 Common Stock (F3) This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.
6 Derivative Option to Purchase Common Stock 2024-01-16 M D 10,000 $0.00 34,885 D $12.07 · — to 2027-02-22 10,000 Common Stock (F3) This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.